Product Center
Yisuda®Suraxavir Marboxil Tablets
Yisuda®Suraxavir Marboxil Tablets are a novel antiviral medication for the treatment of uncomplicated influenza A and B in previously healthy adolescents aged 12 and above, and adults.
Aurantii® Fructus Immaturus Total Flavonoids Tablet
Aurantii® Fructus Immaturus Total Flavonoids Tablet have good therapeutic effects on common symptoms of functional dyspepsia (such as liver-stomach disharmony, spleen-stomach damp-heat, food stagnation, and spleen-stomach deficiency).
Xiyanping Injection
Xiyanping Injection is a traditional Chinese medicine injection made from total sulfated andrographolide, a key component of Andrographis paniculata. It is part of the National “12th Five-Year Plan” Major Innovative Drug Discovery Project.
Qingruitan®Brivaracetam Tablets
Brivaracetam is an innovative third-generation antiepileptic drug that selectively targets synaptic vesicle protein 2A (SV2A) with high affinity.
Bangkaxin®Esomeprazole Magnesium Enteric-coated Tablets
Bangkaxin® Esomeprazole Magnesium Enteric-coated Tablets are a new generation of proton pump inhibitors (PPIs), approved as a Class 4 chemical drug. It is the only esomeprazole magnesium enteric-coated tablet in China that is bioequivalent to the original brand. It is clinically used for the prevention and treatment of acid-related diseases such as gastroesophageal reflux disease (GERD), peptic ulcers, stress ulcers, Helicobacter pylori eradication, and drug-induced gastric mucosal injury. It is widely used in clinical practice and is a first-line choice for acid suppression therapy and ulcer prevention and treatment.
Zebeining® Palbociclib Capsuless
Zebeining® Palbociclib Capsuless are an oral CDK4/6 inhibitor that selectively targets and inhibits the activity of the CDK4/6-Cyclin D1 complex. This prevents tumor cells from passing through the G1 to S phase checkpoint, blocking the cell cycle and inhibiting tumor cell proliferation.It is primarily used for the treatment of hormone receptor-positive (HR+), HER2-negative locally advanced or metastatic breast cancer, in combination with aromatase inhibitors as initial endocrine therapy for postmenopausal women.
Zebeining® Palbociclib Capsuless
Zebeining® Palbociclib Capsuless are an oral CDK4/6 inhibitor that selectively targets and inhibits the activity of the CDK4/6-Cyclin D1 complex. This prevents tumor cells from passing through the G1 to S phase checkpoint, blocking the cell cycle and inhibiting tumor cell proliferation.It is primarily used for the treatment of hormone receptor-positive (HR+), HER2-negative locally advanced or metastatic breast cancer, in combination with aromatase inhibitors as initial endocrine therapy for postmenopausal women.
Xinyang® Abiraterone Acetate Tablets
Xinyang® Abiraterone Acetate Tablets are a highly selective CYP17 enzyme inhibitor that targets multiple sites of androgen biosynthesis throughout the body.
Zebeixin® Lenvatinib Mesilate Capsules
Lenvatinib Mesilate Capsules is an oral multi-target kinase inhibitor, primarily targeting VEGFR1-4, FGFR1-3, PDGFRα/β, c-Kit, and RET. It inhibits tumor angiogenesis, suppresses tumor cell growth, and modulates the tumor immune microenvironment. Clinically, it is used to treat unresectable hepatocellular carcinoma (uHCC). The global multi-center REFLECT study showed significant efficacy of Lenvatinib in treating uHCC. It has been included as a first-line treatment for advanced liver cancer in countries such as China, Japan, and the United States.
Ligesitai® Sorafenib Tosylate Tablets
Ligesitai® Sorafenib Tosylate Tablets are a multi-target oral medication for treating tumors, with dual mechanisms of action. It inhibits tumor angiogenesis by blocking VEGFR and PDGFR and suppresses tumor cell proliferation by blocking the Raf/MEK/ERK signaling pathway, indirectly inhibiting tumor cell growth. It was approved for market in August 2020. It is primarily used for the treatment of renal cancer, liver cancer, and thyroid cancer.
Zebeishu®Regorafenib Tablets
Regorafenib is an oral multi-kinase inhibitor that targets multiple tumor signaling pathways. With a broad spectrum of targets, it inhibits both the VEGF pathway and its bypass mechanisms, effectively disrupting inter-pathway crosstalk.
Xinzhuo® Afatinib Dimaleate Tablets
Xinzhuo® Afatinib Dimaleate Tablets are the first irreversible ErbB family receptor blockers. They covalently bind to the kinase regions of EGFR (ErbB1), HER2 (ErbB2), and HER4 (ErbB4), irreversibly inhibiting tyrosine kinase autophosphorylation, leading to downregulation of ErbB signaling and inhibiting tumor cell proliferation. Xinchuo® was approved for market in August 2021 and is indicated for: Locally advanced or metastatic non-small cell lung cancer (NSCLC) with EGFR gene-sensitive mutations in patients who have not previously received EGFR tyrosine kinase inhibitors (TKI) treatment. Locally advanced or metastatic squamous cell carcinoma of non-small cell lung cancer (NSCLC) with disease progression during or after platinum-based chemotherapy.
Zenuoning®Olaparib Tablets
Olaparib Tablets is the first oral PARP (Poly ADP-ribose polymerase) inhibitor, targeting PARP1, PARP2, and PARP3. It exploits defects in the tumor’s DNA repair pathways to preferentially kill cancer cells. This mechanism enables Olaparib to be especially effective in treating tumors with DNA damage repair deficiencies. Olaparib is mainly used as a first-line or maintenance treatment for ovarian cancer, fallopian tube cancer, or primary peritoneal cancer in patients with BRCA mutations and homologous recombination repair defects (HRD).
